Down-regulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in a murine breast cancer model

Down-regulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in a murine breast cancer model

Objective(s): Immune checkpoint expression on tumor-infiltrating lymphocytes (TILs) has a correlation with the outcome of neoadjuvant chemotherapy (NAC) in breast cancer. However, the reciprocal effect of these regimens on the quality and quantity of immune checkpoints has hitherto not been addresse...

Full description

Bibliographic Details
Main Authors:	Sanambar Sadighi, Ramezanali Sharifian, Monireh Kazemimanesh, Ahad Muhammadnejad, Zahra Shohosseini, Saeid Amanpour, Samad Muhammadnejad
Format:	Article
Language:	English
Published:	Mashhad University of Medical Sciences 2021-04-01
Series:	Iranian Journal of Basic Medical Sciences
Subjects:	animal model breast neoplasms immune checkpoints neoadjuvant chemotherapy tumor infiltrating lymphocytes
Online Access:	https://ijbms.mums.ac.ir/article_17741_3fcd7daa042476d8fe4f8f5c5ed30319.pdf

Similar Items

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
by: Huang L, et al.
Published: (2017-12-01)

Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma
by: Chapman, Thomas Andrew
Published: (2020)

The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer
by: Aurelio Bartolome Castrellon, et al.
Published: (2017-03-01)

Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer
by: Joung, J.-G, et al.
Published: (2022)

Safety of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin  in Patients with IIIa Lung Adenocarcinoma
by: Songliang ZHANG, et al.
Published: (2015-06-01)

Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial
by: Dena Firouzabadi, et al.
Published: (2021-01-01)

Translation of triple-negative breast cancer behavior from the xenograft model to human model
by: Sanaz Rismanchi, et al.
Published: (2016-11-01)

Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights
by: Marieke F. Fransen, et al.
Published: (2021-08-01)

Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
by: Yuka Asano, et al.
Published: (2018-04-01)

Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with IfosfamideDoxorubicin for Osteosarcoma
by: Mozhgan Aalam Samimi, et al.
Published: (2014-03-01)

Expression of Diverse Angiogenesis Factor in Different Stages of the 4T1 Tumor as a Mouse Model of Triple-Negative Breast Cancer
by: Saba Malekian, et al.
Published: (2020-02-01)

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
by: Yi C, et al.
Published: (2019-09-01)

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
by: Arthur Peyrottes, et al.
Published: (2021-07-01)

Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
by: Madison R. Klavans, et al.
Published: (2020-11-01)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
by: S B Dessai, et al.
Published: (2016-01-01)

Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer
by: Yun Liang, et al.
Published: (2018-11-01)

Neoadjuvant Doxorubicin and Docetaxel in Breast Cancer Patients Applied Neutropenic Enterocolitis
by: Hatice Aslan Sırakaya, et al.
Published: (2020-01-01)

Neoadjuvant Chemotherapy with Ifosfamide, Cisplatin, Adriamycin and Mitomycin (IMAP) for High risk Adult Soft Tissue Sarcomas
by: Mohagheghi Mohammad Ali, et al.
Published: (2009-05-01)

Neoadjuvant Chemotherapy with Ifosfamide, Cisplatin, Adriamycin and Mitomycin (IMAP) for High risk Adult Soft Tissue Sarcomas
by: Mohammad Ali Mohagheghi, et al.
Published: (2009-04-01)

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
by: Florian Eichhorn, et al.
Published: (2019-05-01)

Tolerability and Efficacy of Neoadjuvant Chemotherapy with a Tri-Weekly Interval Methotrexate, Doxorubicin, Vinblastine, and Cisplatin Regimen for Patients with Locally Advanced Bladder Cancer
by: Satoko Arai, et al.
Published: (2018-07-01)

Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma
by: Florencia Veigas, et al.
Published: (2021-03-01)

Relation Between CD8+T Lymphocyte Infiltration and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
by: KONG Tiandong, et al.
Published: (2021-05-01)

Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer
by: Daniele Raggi, et al.
Published: (2021-08-01)

Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
by: Arafat Tfayli, et al.
Published: (2020-11-01)

PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer
by: Ding-Xin Liu, et al.
Published: (2020-01-01)

Correlation between Tumor-Infiltrating Lymphocytes and Pathological Response in Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy in H. Adam Malik General Hospital
by: Kamal Basri Siregar, et al.
Published: (2017-08-01)

Neoadjuvant Treatment in Pancreatic Cancer
by: Atsushi Oba, et al.
Published: (2020-02-01)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
by: Junichi Soh, et al.
Published: (2021-08-01)

Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
by: Stefan Münch, et al.
Published: (2017-11-01)

Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1+CD8+ and CD8+ T cells as predictive of response to neoadjuvant chemotherapy in breast cancer
by: Hongling Liang, et al.
Published: (2020-10-01)

Tumor-Infiltrating Lymphocytes and Breast Cancer: Are Immune Checkpoint Inhibitors Ready for Prime Time in Breast Cancer?
by: Cvetanović Ana, et al.
Published: (2016-12-01)

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
by: Vasiliki Pelekanou, et al.
Published: (2017-08-01)

Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
by: Yun Liang, et al.
Published: (2020-06-01)

History and current situation of neoadjuvant treatment for locally advanced esophageal cancer
by: Junyi Li, et al.
Published: (2021-09-01)

Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer
by: Liqiong Yang, et al.
Published: (2021-08-01)

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
by: Xiaotong Li, et al.
Published: (2019-04-01)

Neoadjuvant Systemic Treatment of Primary Angiosarcoma
by: Kimberley M. Heinhuis, et al.
Published: (2020-08-01)

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden
by: Yuka Asano, et al.
Published: (2017-12-01)

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
by: Yan Hu, et al.
Published: (2021-10-01)